An artificial intelligence-based pathology tool for metabolic dysfunction-associated steatohepatitis shows promise for a drug development landscape that is said to be “fraught with trials that have shown borderline results or outright failures based on liver histology.”
An AI tool could help with histologic endpoint assessment in MASH trials (Shutterstock)
Key Takeaways
The European Medicines Agency has issued a draft qualification opinion recommending the use of an AI-based pathology tool in clinical trials of drugs for metabolic dysfunction-associated steatohepatitis (MASH).
The European Medicines Agency is seeking feedback on the use of an artificial intelligence (AI)-based pathology tool that could provide...
